Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors
US12350349B2 · kind B2 · utility
0Cited by
4References
31Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 3, 2017 |
| Grant date | Jul 8, 2025 |
| Priority date | — |
| Expiry date | Jan 29, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2510/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides the use of fratricide-resistant chimeric antigen receptor T (CAR-T) cells targeting antigens expressed by T cell malignancies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.